Compare SRCE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRCE | NVAX |
|---|---|---|
| Founded | 1863 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1995 | 1996 |
| Metric | SRCE | NVAX |
|---|---|---|
| Price | $73.60 | $8.66 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $73.25 | $11.33 |
| AVG Volume (30 Days) | 134.5K | ★ 3.4M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | 19.59 | ★ 309.76 |
| EPS | ★ 6.41 | 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $10.29 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $11.58 | ★ $3.25 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $53.63 | $5.80 |
| 52 Week High | $75.16 | $11.85 |
| Indicator | SRCE | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 48.12 |
| Support Level | $65.26 | $8.09 |
| Resistance Level | N/A | $9.05 |
| Average True Range (ATR) | 1.42 | 0.41 |
| MACD | 0.44 | 0.02 |
| Stochastic Oscillator | 82.40 | 62.61 |
1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.